spacer
home > ebr > summer 2003 > giving vaccines the boost they need
PUBLICATIONS
European Biopharmaceutical Review

Giving Vaccines the Boost They Need

Estimated revenues for therapeutic biologics are set to grow to $50 billion per annum, with immunotherapeutics predicted to grow to 10 per cent of the prescription drug market ($40 billion) within the next decade. Creating immunotherapeutics for diseases such as cancer however, represents a significant challenge for the industry. For example cancer vaccines have to overcome 'self tolerance', the immune system's in-built reluctance to attack its own cells.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Deirdre Gillespie, President and Chief Executive Officer at Oxxon PharmaccinesTM Ltd

Dr Deirdre Gillespie is President and Chief Executive Officer of Oxxon PharmaccinesTM Ltd, a biotechnology company developing innovative immunotherapeutics, specifically therapeutic vaccines (pharmaccines), for the treatment of chronic infectious diseases and cancer. While at Oxxon, Deirdre has overseen the progression of the company's pharmaccines for the treatment of Hepatitis B and malignant melanoma into Phase II clinical trials.

Deirdre was also instrumental in a recently announced private financing that saw Oxxon raise £15 million in an international funding round. She has 16 years' experience in the pharmaceutical and biotechnology industries including senior positions at Vical Inc and DuPont Merck Pharmaceutical Company. Deirdre gained a medical degree from London University and an MBA from London Business School.

spacer
Dr Deirdre Gillespie
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Francine Lane Recipient of 2019 DIA Global Inspire Award

JERSEY CITY – March 21, 2019 – Francine Lane, TrialScope Vice President of Global Transparency, has received a 2019 Global Inspire Award from the Drug Information Association (DIA). Lane, chair of the DIA’s Clinical Trial Disclosure Community, and Robert Paarlberg, past chair, are co-recipients of the Community Engagement Award. The award recognizes DIA community chairs for consistently driving engagement while advancing knowledge and thought leadership within their membership communities.
More info >>

White Papers

Pharmacovigilance and Risk Management Information in Centralised Applications in the EU

United BioSource Corporation (UBC)

Getting a new medication approved for the EU market through the centralised procedure can be complex and needs expertise. The new EU pharmacovigilance legislation (Good Vigilance Practice, GVP) is now in effect and applicants need to be fully compliant. It is critical to have a thorough understanding of the regulatory process and requirements, and the expectations with regards to the pharmacovigilance system and the risk management plan. Ensuring consistency and an appropriate level of detail in the documentation submitted as part of the approval process will help prevent unnecessary delays.
More info >>

 
Industry Events

Nordic Life Science Days 10/12 September 2019

10-12 September 2019, Malmo Sweden

Nordic Life Science Days is the largest Nordic partnering conference for the global Life Science industry. Bringing together the best talents in Life Science, offering amazing networking and partnering opportunities, providing inputs and content on the most recent trends. Nordic Life Science Days attracts leading decision makers from the Life Science sector, not only from biotech, pharma and medtech but also from finances, research, policy and regulatory authorities.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement